IP Library Granted Patent US 9,668,917
Granted Patent B2
US 9,668,917 · App. 14/804,008 · Granted Jun 6, 2017

Drug delivery treatment device

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,668,917
App. No.
14/804,008
Granted
Jun 6, 2017
Kind
B2
Abstract

Disclosed are devices and methods for treatment of eye disease. The suprachoroidal space is used as a conduit within which to place a drug delivery device. One such drug delivery device may be a tube, wicking element, bioabsorbable polymer structure, or other configuration of drug delivery substrate. The delivery device may include a port on the proximal end to assist in repeat injection, and may include a reservoir to either collect flow from the aqueous to concentrate it along the length of the device, or act as a repository for injected agent.

Claims (12)

1. A method of delivering drug into the eye, comprising:

inserting an elongate member through a cornea and through an anterior chamber of the eye, wherein the elongate member has a first end, a second end, and an internal lumen with a first opening near the first end and a second opening near the second end;

positioning the elongate member in the eye such that the first end is in the anterior chamber, the second end is in communication with a suprachoroidal space of the eye, and at least a portion of the elongate member between the first end and the second end is positioned between the sclera and a ciliary body of the eye;

placing a treatment medium onto an outer surface of the eye; and

causing the treatment medium to flow into the internal lumen of the elongate member and into the suprachoroidal space through the internal lumen of the elongate member.

2. A method as in claim 1 , wherein the treatment medium flows into the anterior chamber via tear film.

3. A method as in claim 1 , wherein the elongate member is implanted in the eye such that the second end is positioned in an anterior portion of the eye.

4. A method as in claim 1 , wherein the elongate member is implanted in the eye such that the second end is positioned between a sclera and a choroid of the eye.

5. A method as in claim 1 , wherein the elongate member is implanted in the eye such that the second end is positioned between a sclera and a ciliary body of the eye.

6. A method as in claim 1 , wherein placing a treatment medium onto an outer surface of the eye comprises placing a drop of treatment medium onto an outer surface of the eye.

7. A method as in claim 1 , wherein the elongate member is implanted in the eye such that the elongate member is positioned adjacent a scleral spur of the eye.

8. A method as in claim 1 , wherein the elongate member is implanted in the eye such that no portion of the elongate member between the first end and the second end is positioned inside the sclera.

Assignments (4)
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 10, 2019
From: NOVARTIS AG
To: ALCON INC.
Reel/Frame 051454/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2016
From: TRANSCEND MEDICAL, INC.
To: NOVARTIS AG
Reel/Frame 038967/0487 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2015
From: GIFFORD, HANSON S., III; MACFARLANE, ANGELA; REICH, CARY
To: FORSIGHT LABS, LLC
Reel/Frame 036266/0387 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2015
From: FORSIGHT LABS, LLC
To: TRANSCEND MEDICAL, INC.
Reel/Frame 036266/0530 →